Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Khosla Ventures
Deal Size : $40.0 million
Deal Type : Series A Financing
Rubedo Closes $40M Series A Financing Led by Khosla Ventures, Ahren Innovation
Details : The funding will be utilized to progress the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.
Brand Name : RLS-1496
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Khosla Ventures
Deal Size : $40.0 million
Deal Type : Series A Financing
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Beiersdorf AG
Deal Size : Undisclosed
Deal Type : Partnership
Rubedo Pulls in $40M Series A to Advance Atopic Dermatitis Candidate Targeting Aging Cells
Details : The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.
Brand Name : RLS-1496
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : RLS-1496
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Beiersdorf AG
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Presented in vivo efficacy data for its small molecule therapy engineered via ALEMBIC™ drug discovery platform, targetes senescent cells that drive cellular aging to treat dermatological diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RBO-0618
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : California Institute for Regenerative Medicine
Deal Size : $1.4 million
Deal Type : Funding
Details : The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.
Brand Name : RBO-0618
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : RBO-0618
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : California Institute for Regenerative Medicine
Deal Size : $1.4 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery Platform
Sponsor : Khosla Ventures
Deal Size : $12.0 million
Deal Type : Financing
Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures
Details : The funding will be used to advance the company’s lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 03, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery Platform
Sponsor : Khosla Ventures
Deal Size : $12.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?